Abstract:BackgroundInterferon (IFN)-α is thought to have a pivotal role in systemic lupus erythematosus (SLE), and type III IFNs (IFN-λ) were recently also associated with SLE. In this study, we measured levels of IFN-α, IFN-λ1, and related cytokines, such as IL-17A, IL-23, and interferon-γ-induced protein 10 (IP-10), in a Karolinska University Hospital cohort of patients with SLE and control subjects. The objective of the study was to investigate if cytokine measurements could identify different subsets of patients with active SLE and higher disease damage.MethodsWe included 261 patients with SLE and 261 population control subjects. All participants underwent a standardized clinical examination. Medical files were reviewed. Patients with SLE were assessed for current organ manifestations, disease activity, and damage. Routine blood parameters, complement levels, and serology were analyzed at the time of inclusion. Levels of IFN-λ1, IFN-α, IL-17A, IL-23, and IP-10 were measured by enzyme-linked immunosorbent assay.ResultsIFN-λ1 and IFN-α were detected in 29% and 44% of patients, respectively, but their levels did not correlate. High serum levels of IFN-λ1 were positively associated with antinucleosome antibodies and lymphopenia but negatively with musculoskeletal damage. Positive correlations between levels of IFN-λ1, IL-17A, and IL-23 were observed. Patients with high levels of these three cytokines had more disease damage, especially renal impairment. High levels of IFN-α were associated with mucocutaneous disease; leukopenia; and low complement, Ro/SSA, and La/SSB. Vascular events and antiphospholipid antibodies were uncommon. We identified two subgroups with high disease activity: one with double-high IFN-λ1 and IFN-α and another with IP-10high. The former had more neuropsychiatric manifestations, and the latter had more arthritis. Increased levels of both types I and III IFNs were found in a proportion of population control subjects. Therefore, high IFN levels do not seem to be SLE-specific biomarkers.ConclusionsMeasurements of circulating IFN-λ1 and IFN-α define subsets of patients with SLE with different characteristics. Levels of IFN-λ1 correlate with T-helper type 17 cytokines and identify a subgroup with more damage. High disease activity is associated with either simultaneous upregulation of IFN-λ1 and IFN-α or independently with IP-10. Our findings could be of major importance when tailoring therapy for patients with SLE with agents targeting IFN pathways.

Higher Activation of the Interferon-Gamma Signaling Pathway in Systemic Lupus Erythematosus Patients with a High Type I IFN Score: Relation to Disease Activity

Association Of Increased Interferon-Inducible Gene Expression With Disease Activity And Lupus Nephritis In Patients With Systemic Lupus Erythematosus

Increased interferon-inducible gene expression, an useful marker in the diagnosis and disease activity evaluation of systemic lupus erythematosus

[Peripheral Blood Mrna and Interferon Gene Expression in Systemic Lupus Erythematosus].

The expression levels of interferon inducible genes in peripheral blood cells and their correlation with clinical features in human systemic lmpus erytbematosus

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)

The Expression of Interferon-Αin the Peripheral Blood and Correlation with Disease Activity in Systemic Lupus Erythematosus Patients

Identification of Interferon-Inducible Genes As Diagnostic Biomarker for Systemic Lupus Erythematosus

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus

Association of increased interferon-inducible gene expression with disease activity in patients with lupus nephritis

Expressions of interferon-inducible genes in patients with systemic lupus erythematosus and their assoc-iation with disease activity

Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients.

Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients

Characterization of CD4+ T cells expressing an elevated interferon-stimulated gene signature in SLE patients

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

Involvement of type Ⅰ interferon in modulating activation and TLRs expression on T cells in systemic lupus erythematosus

[Interferon-Inducible Genes Lymphocyte Antigen 6 Complex E and Tetratricopeptide Repeats 1 Are Correlated with Clinical Features of Patients with Systemic Lupus Erythematosus].

[Evaluating Type I Interferon-Inducible Gene Expression in Patients with Systemic Lupus Erythematosus.].

Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells

Expression of Cyclic GMP-AMP Synthase in Patients With Systemic Lupus Erythematosus

The expression of IKB kinase in the peripheral blood and its correlation with the production of interferon-α in systemic lupus erythematosus patients